Adequan Availability could be Limited in Coming Months

Supplies of Adequan i.m., the only FDA-approved polysulfated glycosaminoglycan product, are expected to be limited in the coming months due to renovations to Luitpold Pharmaceuticals' Shirley, N.Y., factory, according to a press release from the company.

"Our factory in New York has undergone a significant renovation to meet enhanced quality standards and address observations of the FDA," the statement read. "This has resulted in the depletion of our existing inventories. We have carefully managed supply to allocate inventory optimally, but the product will be out of stock for a short period of time. We expect to resume shipments of the 5 mL in early July, followed by the 50 mL in August.

"We appreciate the patience and loyalty of our customers during this supply interruption," the company said in the release.

Adequan was by the FDA for equine use in 1984, and is designed to treat non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal (knee) and hock joints in horses.

The release noted that territory managers will communicate updates on products' expected release dates to their veterinary accounts and to horse owners at our sponsored events. Updates will also be available online at www.adequan.com or www.nogenericadequan.com.

About the Author

Erica Larson, news editor, holds a degree in journalism with an external specialty in equine science from Michigan State University in East Lansing. A Massachusetts native, she grew up in the saddle and has dabbled in a variety of disciplines including foxhunting, saddle seat, and mounted games. Currently, Erica competes in eventing with her OTTB, Dorado.

Stay on top of the most recent Horse Health news with FREE weekly newsletters from TheHorse.com. Learn More